trachomatis gene products that exhibit variability ... are described below and summarized in Table 1. Inclusion-vesicle trafficking is perceived to be important for the intracellular growth ...

Chlamydia trachomatis bacteria (represented by small dark spherical shapes colorized blue) undergo development within a membrane-enclosed "inclusion body." The dark green shape on the right of the ...

The bacterium chlamydia trachomatis is a major cause of sexually ... These areas, called inclusion contact sites, were packed with special fats and proteins that prepared the membranes for fusion.

Since Chlamydia trachomatis or Chlamydia pneumoniae (which are often asymptomatic) frequently cause ReA, a new study examined whether there was a connection between these two infections and uSpA.

If immune cells detect Chlamydia before it forms the inclusion, they trigger T cells to produce interferon-γ (IFN-γ), a powerful cytokine. IFN-γ activates the protein mysterin (also called RFN213), ...

Chlamydia is an infection caused by the bacterium Chlamydia trachomatis. It's one of the most widespread of all sexually transmitted diseases, according to the Centers for Disease Control and ...

The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Chlamydia – caused by the organism Chlamydia trachomatis – caused an estimated 128.5 million new infections in 2020, according to the World Health Organization (WHO), with a global prevalence ...

Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the immunogenicity and ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...